O	0	5	Phase
O	6	9	III
O	10	15	trial
O	16	18	of
B-intervention	19	31	nanoparticle
I-intervention	32	39	albumin
I-intervention	39	40	-
I-intervention	40	45	bound
I-intervention	46	56	paclitaxel
O	57	65	compared
O	66	70	with
B-control	71	84	polyethylated
I-control	85	91	castor
I-control	92	95	oil
I-control	95	96	-
I-control	96	101	based
I-control	102	112	paclitaxel
O	113	115	in
O	116	121	women
O	122	126	with
O	127	133	breast
O	134	140	cancer
O	140	141	.

O	142	145	ABI
O	145	146	-
O	146	149	007
O	149	150	,
O	151	154	the
O	155	160	first
O	161	173	biologically
O	174	185	interactive
O	186	193	albumin
O	193	194	-
O	194	199	bound
O	200	210	paclitaxel
O	211	213	in
O	214	215	a
O	216	225	nanameter
O	226	234	particle
O	234	235	,
O	236	240	free
O	241	243	of
O	244	252	solvents
O	252	253	,
O	254	257	was
O	258	266	compared
O	267	271	with
O	272	285	polyethylated
O	286	292	castor
O	293	296	oil
O	296	297	-
O	297	302	based
O	303	311	standard
O	312	322	paclitaxel
O	323	325	in
B-eligibility	326	334	patients
I-eligibility	335	339	with
I-eligibility	340	350	metastatic
I-eligibility	351	357	breast
I-eligibility	358	364	cancer
I-eligibility	365	366	(
I-eligibility	366	369	MBC
I-eligibility	369	370	)
O	370	371	.

O	372	376	This
O	377	382	phase
O	383	386	III
O	387	392	study
O	393	396	was
O	397	406	performed
O	407	409	to
O	410	417	confirm
O	418	429	preclinical
O	430	437	studies
O	438	451	demonstrating
O	452	460	superior
O	461	469	efficacy
O	470	473	and
O	474	481	reduced
O	482	490	toxicity
O	491	493	of
O	494	497	ABI
O	497	498	-
O	498	501	007
O	502	510	compared
O	511	515	with
O	516	524	standard
O	525	535	paclitaxel
O	535	536	.

O	537	545	Patients
O	546	550	were
O	551	559	randomly
O	560	568	assigned
O	569	571	to
O	572	573	3
O	573	574	-
O	574	578	week
O	579	585	cycles
O	586	588	of
O	589	595	either
O	596	599	ABI
O	599	600	-
O	600	603	007
O	604	607	260
O	608	610	mg
O	610	611	/
O	611	612	m
O	612	613	(
O	613	614	2
O	614	615	)
O	616	629	intravenously
O	630	637	without
O	638	651	premedication
O	652	653	(
O	653	654	n
O	655	656	=
B-intervention-participants	657	660	229
O	660	661	)
O	662	664	or
O	665	673	standard
O	674	684	paclitaxel
O	685	688	175
O	689	691	mg
O	691	692	/
O	692	693	m
O	693	694	(
O	694	695	2
O	695	696	)
O	697	710	intravenously
O	711	715	with
O	716	729	premedication
O	730	731	(
O	731	732	n
O	733	734	=
B-control-participants	735	738	225
O	738	739	)
O	739	740	.

O	741	744	ABI
O	744	745	-
O	745	748	007
O	749	761	demonstrated
O	762	775	significantly
O	776	782	higher
B-outcome	783	791	response
I-outcome	792	797	rates
O	798	806	compared
O	807	811	with
O	812	820	standard
O	821	831	paclitaxel
O	832	833	(
B-iv-bin-percent	833	835	33
I-iv-bin-percent	835	836	%
O	837	838	v
B-cv-bin-percent	839	841	19
I-cv-bin-percent	841	842	%
O	842	843	,
O	844	856	respectively
O	856	857	;
O	858	859	P
O	860	861	=
O	862	863	.
O	863	866	001
O	866	867	)
O	868	871	and
O	872	885	significantly
O	886	892	longer
B-outcome	893	897	time
I-outcome	898	900	to
I-outcome	901	906	tumor
I-outcome	907	918	progression
O	919	920	(
B-iv-cont-median	920	922	23
I-iv-cont-median	922	923	.
I-iv-cont-median	923	924	0
O	925	926	v
B-cv-cont-median	927	929	16
I-cv-cont-median	929	930	.
I-cv-cont-median	930	931	9
I-cv-cont-median	932	937	weeks
O	937	938	,
O	939	951	respectively
O	951	952	;
O	953	959	hazard
O	960	965	ratio
O	966	967	=
O	968	969	0
O	969	970	.
O	970	972	75
O	972	973	;
O	974	975	P
O	976	977	=
O	978	979	.
O	979	982	006
O	982	983	)
O	983	984	.

O	985	988	The
B-outcome	989	998	incidence
I-outcome	999	1001	of
I-outcome	1002	1007	grade
I-outcome	1008	1009	4
I-outcome	1010	1021	neutropenia
O	1022	1025	was
O	1026	1039	significantly
O	1040	1045	lower
O	1046	1049	for
O	1050	1053	ABI
O	1053	1054	-
O	1054	1057	007
O	1058	1066	compared
O	1067	1071	with
O	1072	1080	standard
O	1081	1091	paclitaxel
O	1092	1093	(
B-iv-bin-percent	1093	1094	9
I-iv-bin-percent	1094	1095	%
O	1096	1097	v
B-cv-bin-percent	1098	1100	22
I-cv-bin-percent	1100	1101	%
O	1101	1102	,
O	1103	1115	respectively
O	1115	1116	;
O	1117	1118	P
O	1119	1120	<
O	1121	1122	.
O	1122	1125	001
O	1125	1126	)
O	1127	1134	despite
O	1135	1136	a
O	1137	1139	49
O	1139	1140	%
O	1141	1147	higher
O	1148	1158	paclitaxel
O	1159	1163	dose
O	1163	1164	.

B-outcome	1165	1172	Febrile
I-outcome	1173	1184	neutropenia
O	1185	1188	was
O	1189	1197	uncommon
O	1198	1199	(
O	1199	1200	<
O	1201	1202	2
O	1202	1203	%
O	1203	1204	)
O	1204	1205	,
O	1206	1209	and
O	1210	1213	the
O	1214	1223	incidence
O	1224	1227	did
O	1228	1231	not
O	1232	1238	differ
O	1239	1246	between
O	1247	1250	the
O	1251	1254	two
O	1255	1260	study
O	1261	1265	arms
O	1265	1266	.

B-outcome	1267	1272	Grade
I-outcome	1273	1274	3
I-outcome	1275	1282	sensory
I-outcome	1283	1293	neuropathy
O	1294	1297	was
O	1298	1302	more
O	1303	1309	common
O	1310	1312	in
O	1313	1316	the
O	1317	1320	ABI
O	1320	1321	-
O	1321	1324	007
O	1325	1328	arm
O	1329	1333	than
O	1334	1336	in
O	1337	1340	the
O	1341	1349	standard
O	1350	1360	paclitaxel
O	1361	1364	arm
O	1365	1366	(
B-iv-bin-percent	1366	1368	10
I-iv-bin-percent	1368	1369	%
O	1370	1371	v
B-cv-bin-percent	1372	1373	2
I-cv-bin-percent	1373	1374	%
O	1374	1375	,
O	1376	1388	respectively
O	1388	1389	;
O	1390	1391	P
O	1392	1393	<
O	1394	1395	.
O	1395	1398	001
O	1398	1399	)
O	1400	1403	but
O	1404	1407	was
O	1408	1414	easily
O	1415	1422	managed
O	1423	1426	and
O	1427	1435	improved
O	1436	1443	rapidly
O	1444	1445	(
O	1445	1451	median
O	1451	1452	,
O	1453	1455	22
O	1456	1460	days
O	1460	1461	)
O	1461	1462	.

O	1463	1465	No
B-outcome	1466	1482	hypersensitivity
I-outcome	1483	1492	reactions
O	1493	1501	occurred
O	1502	1506	with
O	1507	1510	ABI
O	1510	1511	-
O	1511	1514	007
O	1515	1522	despite
O	1523	1526	the
O	1527	1534	absence
O	1535	1537	of
O	1538	1551	premedication
O	1552	1555	and
O	1556	1563	shorter
O	1564	1578	administration
O	1579	1583	time
O	1583	1584	.

O	1585	1588	ABI
O	1588	1589	-
O	1589	1592	007
O	1593	1605	demonstrated
O	1606	1613	greater
O	1614	1622	efficacy
O	1623	1626	and
O	1627	1628	a
O	1629	1638	favorable
O	1639	1645	safety
O	1646	1653	profile
O	1654	1662	compared
O	1663	1667	with
O	1668	1676	standard
O	1677	1687	paclitaxel
O	1688	1690	in
O	1691	1695	this
O	1696	1703	patient
O	1704	1714	population
O	1714	1715	.

O	1716	1719	The
O	1720	1728	improved
O	1729	1740	therapeutic
O	1741	1746	index
O	1747	1750	and
O	1751	1762	elimination
O	1763	1765	of
O	1766	1780	corticosteroid
O	1781	1794	premedication
O	1795	1803	required
O	1804	1807	for
O	1808	1815	solvent
O	1815	1816	-
O	1816	1821	based
O	1822	1829	taxanes
O	1830	1834	make
O	1835	1838	the
O	1839	1844	novel
O	1845	1852	albumin
O	1852	1853	-
O	1853	1858	bound
O	1859	1869	paclitaxel
O	1870	1873	ABI
O	1873	1874	-
O	1874	1877	007
O	1878	1880	an
O	1881	1890	important
O	1891	1898	advance
O	1899	1901	in
O	1902	1905	the
O	1906	1915	treatment
O	1916	1918	of
O	1919	1922	MBC
O	1922	1923	.
